Hanmi Pharmaceutical agrees to mega-license deal

Home > Business > Industry

print dictionary print

Hanmi Pharmaceutical agrees to mega-license deal

Hanmi Pharmaceutical entered into an agreement with Sanofi, a French drug maker, to license the Korean company’s Quantum Project, a diabetes solutions portfolio in development, Hanmi said Thursday.

Hanmi will receive an upfront payment of 400 million euros ($435 million) and is eligible for payments of up to 3.5 billion euros, according to certain sales and development milestones. After the product is released, a separate two-digit percentage royalty for the sales will also be provided to the Korean drug maker.

Sanofi will receive a worldwide license to develop and commercialize three investigative diabetes treatments, including a drug called efpeglenatide that belongs to a novel class of medicines called GLP1-agnostics, used to control blood sugar.

Hanmi will keep an exclusive option to jointly commercialize the products in Korea and China.

The Quantum Project is a new pipeline of a long lasting-diabetes treatment applying Hanmi’s technology, LAPSCOVERY (Long Acting Protein/Peptide Discovery), which maximizes treatment by limiting the number and dose of administered medicines.

BY KIM JEE-HEE, BLOOMBERG [kim.jeehee@joongang.co.kr]

More in Industry

Booze boom

Move over Federer

Hanjin KAL slams largest shareholder, accusing it of peddling lies

Tech firms brief president on state of AI research

Dongsuh recognizes female authors at Scent of Life Awards

Log in to Twitter or Facebook account to connect
with the Korea JoongAng Daily
help-image Social comment?
lock icon

To write comments, please log in to one of the accounts.

Standards Board Policy (0/250자)

What’s Popular Now